We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Revised Criteria Proposed for Diagnosis of Alzheimer's Disease

By HospiMedica staff writers
Posted on 06 Aug 2007
New criteria have been proposed for the diagnosis of Alzheimer's disease (AD). More...


Distinctive and reliable biomarkers are now available for the diagnosis of Alzheimer's disease. These are obtained by cerebrospinal fluid (CSF) analysis, positron emission tomography (PET) neuroimaging, and structural magnetic resonance imaging (MRI).

Recommendations for the new criteria, based on a consensus of an international working group of AD experts, are intended to replace the existing recommendations originally published in 1984 by the U.S. National Institute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders. The team of experts aimed to capture both the earliest stages, before full-blown dementia, as well as the full spectrum of the illness. Validation studies in existing and prospective cohorts are needed to advance these criteria and optimize their sensitivity, specificity, and accuracy.

The new criteria are centered on a clinical core of early and significant episodic memory impairment. The team stipulated that there must also be at least one or more abnormal biomarkers among structural neuroimaging with MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid ß or tau proteins. The timeliness of these criteria is highlighted by the many drugs in development that are directed at changing pathogenesis, particularly the production and clearance of amyloid ß as well as at the hyperphosphorylation state of tau.

Fifteen publications have reported the sensitivity and specificity of the p-tau 231 CSF-based test to be within the range of 85-95 % in various patient populations; one publication showed that the test also has a positive correlation with autopsy confirmation of AD, which is the current gold standard of diagnosis methods.

A report of the group's conclusions was published in the August 2007 issue of The Lancet Neurology. Measurement of the concentration of p-tau, notably p-tau 231, increases the specificity for AD, especially in contrast to fronto-temporal lobar degeneration, the authors wrote.

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.